The clinical spectrum of dermatomyositis;Das klinische spektrum der dermatomyositis

JDDG - Journal of the German Society of Dermatology

Volumn 3, Issue 3, 2005, Pages 181-194

  Kaufmann, Julia ^a   Hunzelmann, Nicolas ^a   Genth, Ekkehard ^b   Krieg, Thomas ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b LVA Rheinprovinz ^*  (Germany)

Author keywords

Antibodies; Dermatomyositis; Diagnostic criteria; Organ involvement; Therapy

Indexed keywords

ALLOPURINOL; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERFERON; MESNA; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALOPECIA; ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; CANCER; CANCER DIAGNOSIS; CLINICAL FEATURE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DEPRESSION; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; GASTROINTESTINAL SYMPTOM; HEMORRHAGIC CYSTITIS; HUMAN; LIVER CIRRHOSIS; LIVER TOXICITY; LYMPHOMA; MYOSITIS; NEPHROTOXICITY; NEUTROPENIA; PATHOGENESIS; PLASMAPHERESIS; PNEUMONIA; REVIEW; STOMATITIS; TREATMENT OUTCOME; VIRUS INFECTION;

ADULT; AGE FACTORS; AZATHIOPRINE; BIOPSY; CHILD; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DERMATOLOGIC AGENTS; DERMATOMYOSITIS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; METHOTREXATE; MIDDLE AGED; MUSCLES; MYCOPHENOLIC ACID; PARANEOPLASTIC SYNDROMES; PLASMAPHERESIS; PROGNOSIS; SEX FACTORS; TIME FACTORS;

EID: 14944349745     PISSN: 16100379     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1610-0378.2005.05006.x     Document Type: Review

References (61)

1. Airio A, Pukkala E, Isomäki H. Elevated cancer incidence in patients with dermatomyositis: A population based study. J Rheumatol 1995; 22: 1300-1303.
2. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 344-347.
3. Briggs MB, Burkard KT, Butler JS. Rrp6p, the yeast homologue of the human PM-Scl 100 kDa autoantigen is essential for efficient 5.8S rRNA 3' end formation. J Biol Chem 1998; 273: 13255-13263.
4. Callen JP. Dermatomyositis. Lancet 2000; 355: 53-57.
5. Cheong WK, Hughes GRV, Norris PG, Hawk JLM. Cutaneous photosen-sitivity in dermatomyositis. Br J Dermatol 1994; 131: 205-208.
6. Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF jr. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort-study in denmark. Cancer Causes Controll 1995; 5: 9-13.
7. Dalakas MC. Controlled studies with high-dose intravenous immunglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 1998; 51: 37-45.
8. Dantzig P. Juvenile dermatomyositis treated with cyclosporine. J Am Acad Dermatol 1990; 22: 310-311.
9. Garcia J. MRI in inflammatory myopthies. Skeletal Radiol 2000; 29: 425-438.
10. Genth E. Autoantikörper bei Dermato-und Polymyositiden in: Conrad K. (Ed): Autoantikörper. Pabst Science Publishers, Lengerich, Berlin, Düsseldorf, Riga 1998; 303-321.
11. Genth. E. Entzündliche Muskelerkrankungen aus internistischer Sicht. Internist 2000; 41 (5): 445-454.
12. Gonzalez-Lopez L, Gamez-Nava JI, Sanchez L, Rosas E, Suarez-Almazor M, Cardona-Munoz C, Ramos-Remus C. Cardiac manifestations in dermatopolymyositis. Clin Exp Rheumatol 1996; 14: 373-379.
13. Guldner HH, Netter HJ, Szostecki C, Jaeger E, Will H. Human anti-p68 autoantibodies recognize a common epitope of u1 RNA containing small nuclear ribonucleoprotein and influenza B virus. J Exp Med 1990; 171: 819-829.
14. Hirakata M, Suwa A, Nagai S, Kron MA, Trieu EP, Mimori T, Akizuki M, Targoff IN. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 1999; 162: 2315-2320.
15. Kovacs SO, Kovacs SC. Dermatomyositis J Am Acad Dermatology 1998; 39: 899-920.
16. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991; 70: 360-374.
17. Marie I, Hatron P-Y, Hachulla E, Wallaert B, Michon-Pasturel U, Devulder B. Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol 1998; 25: 1336-1343.
18. Mierau R, Dick T, Bartz-Bazzanella P, Keller E, Albert ED, Genth E. Strong association of dermatomyositis-specific Mi-2 autoantibodies with tryptophan at position 9 of the HLA-DR beta chain. Arthritis Rheum 1996; 39: 868-876.
19. Miller FW, Twitty SA, Biswas T, Plotz PH. Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti Jo-1 autoantibodies. J Clin Invest 1990; 85: 468-475.
20. Patheiger U, Hahn M, Jünger M, Rahmel B, Rassner G. Morphologische und funktioneile Veränderungen an Nagelfalzkapillaren bei Dermatomyositis. Phlebol 1991; 20: 91-93.
21. Peng J-C, Sheem T-S, Hsu MM. Nasopharyngeal carcinoma with dermatomyositis: Analysis of 12 cases. Arch Otolaryngol Head Neck Surg 1995; 121: 1298-1301.
22. Plotz PH, Rider LG, Targoff IN, Raben N, O'Hanlon TP, Miller FW. NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis and therapy. Ann Intern Med 1995; 122: 715-724.
23. Siguregeirsson B, Lindelöf B, Edhag O, Allander E. Risk of cancer with dermatomyositis or polymyositis. N Engl J Med 1992; 325: 363-367.
24. Spiera R, Kagen L. Extramuscular manifestations in idiopathic inflammatory myopathies. Curr Opin Rheumatol 1998; 10:556-561.
25. Sugiura T, Murakawa Y, Nagai A, Kondo M, Kobayashi S. Fas and Fas li-gand interaction induces apoptosis in inflammatory myopathies. Arthritis Rheum 1999; 42: 291-298.
26. Yamanishi Y, Maeda H, Katayama S, Ishioka S, Yamakido M. Sclerodermapolymyositis overlap syndrome associated with anti-KU antibody and rimmed vacuole formation. J Rheumatol 1996; 23: 1991-1994.
27. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV, Evans WE. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 608-614.
28. Mastaglia FL, Beverly AP. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin N Am 2002; 28: 723-741.
29. Dalakas MC. Therapeutic Approaches in Patients with Inflammatory Myopathies. Semin Neurol 2003; 23: 199-206.
30. Mastaglia FL, Garlepp MJ, Phillips BA, Zilko PJ. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 2003; 27: 407-425.
31. Dalakas MC. Polymyositis and dermatomyositis. Lancet 2003; 362: 971-982.
32. Maddison P. Cancer types in dermatomyositis and polymyositis. Lancet 2001; 57: 1443.
33. Callen J. Relation between dermatomyositis and polymyositis and cancer. Lancet 2001; 357: 85-86.
34. Miller FW, Rider LG. Diagnostic criteria for polymyositis and dermatomyositis. Lancet 2003; 362: 1762-1763.
35. Targoff IN. Idiopathic Inflammatory Myopathy: Autoantibody Update. Opin Rheum 2002; 4: 434-441.
36. Medsger TA, Dawson WN, Masi AT. The epidemiology of polymyositis. Am J Med 1979; 48: 715-23.
37. Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologie aspects. Dermatol Clin 2002; 20: 387-408.
38. Dayal NA, Isenberg DA. SLE/myositis overlap: are the manifestations of SLE different in overlap disease? Lupus 2002; 11: 293-98.
39. Rosenberg NL, Carry MR, Ringel SP. Association of inflammatory myopathies with other connective tissue disorder and malignancies. In: Dalakas MC, ed. Polymyositis and dermatomyositis. Boston: Butterworth, 1988: 37-69.
40. Callen JP. When and how should the patient with dermatomyositis or amyopathic dermatomyositis be assessed for possible cancer? Arch Dermatol 2002; 138: 969-971.
41. Dalakas MC. Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin N Am 2002; 28: 779-798.
42. Hohlfeld R, Engel AG, Goebels N, Behrens L. Cellular immune mechanisms in inflammatory myopathies. Curr Opin Rheumatol 1997; 9: 520-526.
43. Lepidi H, Frances V, Figarella-Branger D, Bartoli C, Machado-Bàeta GP, Pellissier JR. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 1998; 24: 73-79.
44. Liang Y, Inukai A, Kuru S, Kato T, Doyu M, Sobue G. The role of lymphotoxin in pathogenesis in polymyositis. Acta Neuropathol (Berl) 2000; 100: 521-527.
45. Lundberg IE. The role of cytokines, chemokines, and adhesion molecules in the pathogenesis of idiopathic inflammatory myopathies. Curr Rheumatol Rep 2000; 2: 216-224.
46. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000; 22: 441-457.
47. Argov Z. Drug-induced myopathies. Curr Opin Neurol 2000; 13: 541-545.
48. Giordano N, Sensi M, Mattii G, Battisti E, Villanova M, Gennari C. Polymyositis associated with simvastatin. Lancet 1997; 349: 1600-1601.
49. Finger DR, Plotz PH, Heywood G. Myositis following treatment with high-dose interleukin-2 for malignancy. J Rheumatol 1994; 4: 752-753.
50. Mutsuya M, Abe T, Yonezawa K, Ono A, Ikeda N, Yoshida Y, Akahonai Y, Kurokawa S, Hayashi T. The first case of polymyositis associated with interferon therapy. Intern Med 1994; 33: 806-808.
51. Mowzoon N, Sussman A, Bradley WG. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001; 185: 119-122.
52. Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R, Fraser DD, Dalakas M, Plotz PH. Controlled trial of plasma exchange and leukopheresis in polymyositis and dermatomyositis. N Engl J Med 1992; 26: 1380-1384.
53. Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular disease. Arthritis Rheum 1998; 41: 1215-20.
54. Schmidt WA, Wetzel W, Friedlander R. Clinical and serological aspects of Patients with anti-Jo-1 antibodies: an evolving spectrum of disease manifestations. Clin Rheumatol 2000; 19: 371-377.
55. Dacey MJ, Gallen JP. Hydroxyurea-induced dermatomyositis-like eruption. J Am Acad Dermatol 2003; 48: 439-441.
56. Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev 2002; 1: 329-337.
57. Garlepp MJ, Mastaglia FL. Autoantibodies in inflammatory myopathies. Am J Med Sci 2000; 319: 227-233.
58. Tanimoto K, Nakano K, Kano S. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995; 22: 668-674.
59. Pautas E, Cherin P, Piette JC, Pelletier S, Wechsler B, Cabane J, Herson S. Features of polymyositis and dermatomyositis in the elderly: a case-control study. Clin Exp Rheumatol 2000; 18: 241-244.
60. Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology 2002; 1: 22-26.
61. Hengstman GJ, van den Hoogen FH, Barrera P, Netea MG, Pieterse A, van de Putte LB, van Engelen BG. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 2003; 50: 10-15.y